Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model

Kenzo Iizuka, Cheng Jin, Kokoro Eshima, Mei Hong, Kiyoshi Eshima, Masakazu FukushimaDrug 2018 · DOI

Abstract

Collectively, the ip delivery of DFP-10825, TS shRNA conjugated with cationic liposome, shows a favorable antitumor activity without systemic adverse events via the stable localization of TS shRNA for a sufficient time and concentration in the peritoneal cavity of the peritoneally disseminated human ovarian cancer-bearing mice.
BibTeX
@inproceedings{iizuka2018anticancer,
  author = {Kenzo Iizuka and Cheng Jin and Kokoro Eshima and Mei Hong and Kiyoshi Eshima and Masakazu Fukushima},
  title = {{Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model}},
  booktitle = {Drug},
  year = {2018},
  doi = {10.2147/dddt.s156635},
}

Loading related content...

Figure